{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:30:48Z","timestamp":1791923448182,"version":"4.3.4"},"reference-count":60,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:sec id=\"ab-ysc250005-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Psilocybin use has surged in the US following decriminalization efforts and promising clinical trial results. Mirroring early cannabis legalization, public access and enthusiasm are outpacing regulatory oversight and scientific understanding, posing potential risks to public health.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ysc250005-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To review emerging evidence on the public health implications of unregulated psilocybin mushroom use, including trends in use, product variability, co-use with other substances, and age-related differences in outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ysc250005-6\">\n                    <jats:title>Evidence Review<\/jats:title>\n                    <jats:p>Sources included peer-reviewed articles, national surveillance data (eg, poison control center reports), and publicly available chemical testing data from decriminalized jurisdictions. The review emphasizes epidemiological and pharmacological findings published between January 1, 2014, and December 31, 2024, with attention to parallels from cannabis legalization research. Studies were selected based on relevance to nonclinical psilocybin use, product composition, adverse outcomes, and co-use patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ysc250005-7\">\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Psilocybin mushroom use has sharply increased in the US, particularly among adults aged 19 to 50 years, with more than 7 million individuals reporting use in the past year. This trend has coincided with a substantial increase in poison control center calls related to psychedelics. Testing data from decriminalized regions indicate more than 20-fold variability in psilocybin potency and inconsistent levels of minor tryptamines across mushroom strains. Clinical trial data on synthetic psilocybin do not generalize to public use due to strict participant selection and controlled environments. Co-use with cannabis is common and may increase the risk of adverse events. Evidence also suggests that age may moderate both risks and benefits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ysc250005-8\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The expanding use of unregulated psilocybin mushrooms, combined with high variability in composition and common co-use with other substances, raises urgent public health concerns. Existing clinical data are insufficient to guide harm reduction or policy. There is a pressing need to pivot from controlled efficacy trials to real-world research on psilocybin use, including public education, potency testing, and age-specific risk assessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2025.3038","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:00:51Z","timestamp":1762358451000},"page":"78","source":"Crossref","is-referenced-by-count":22,"title":["Psilocybin Outside the Clinic"],"prefix":"10.1001","volume":"83","author":[{"given":"Kent E.","family":"Hutchison","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake F.","family":"Hooper","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollis C.","family":"Karoly","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"ysc250005r1","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.3390\/molecules26102948","article-title":"The therapeutic potential of psilocybin.","volume":"26","author":"Lowe","year":"2021","journal-title":"Molecules"},{"issue":"12","key":"ysc250005r3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/15563650.2024.2412423","article-title":"2023 Annual report of the National Poison Data System\u00ae (NPDS) from America\u2019s Poison Centers\u00ae: 41st annual report.","volume":"62","author":"Gummin","year":"2024","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"ysc250005r4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41514-025-00244-x","article-title":"Psilocybin treatment extends cellular lifespan and improves survival of aged mice.","volume":"11","author":"Kato","year":"2025","journal-title":"NPJ Aging"},{"issue":"7","key":"ysc250005r5","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.7326\/ANNALS-24-03145","article-title":"The rise of psilocybin use in the United States: a multisource observational study.","volume":"178","author":"Rockhill","year":"2025","journal-title":"Ann Intern Med"},{"issue":"5","key":"ysc250005r6","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jadohealth.2024.01.027","article-title":"Psilocybin exposures reported to US poison centers: national trends over a decade.","volume":"74","author":"Farah","year":"2024","journal-title":"J Adolesc Health"},{"issue":"4","key":"ysc250005r7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1080\/15563650.2024.2346612","article-title":"The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics.","volume":"62","author":"Wilkes","year":"2024","journal-title":"Clin Toxicol (Phila)"},{"key":"ysc250005r8","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1359088","article-title":"Efficacy and acceptability of psilocybin for primary or secondary depression: a systematic review and meta-analysis of randomized controlled trials.","volume":"15","author":"Fang","year":"2024","journal-title":"Front Psychiatry"},{"issue":"10","key":"ysc250005r9","doi-asserted-by":"publisher","first-page":"958","DOI":"10.30773\/pi.2021.0209","article-title":"Psilocybin for end-of-life anxiety symptoms: a systematic review and meta-analysis.","volume":"18","author":"Yu","year":"2021","journal-title":"Psychiatry Investig"},{"issue":"3","key":"ysc250005r10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/09540261.2021.1919062","article-title":"Psilocybin and MDMA for the treatment of trauma-related psychopathology.","volume":"33","author":"Bird","year":"2021","journal-title":"Int Rev Psychiatry"},{"issue":"10","key":"ysc250005r11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial.","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"ysc250005r12","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.","volume":"28","author":"Johnson","year":"2014","journal-title":"J Psychopharmacol"},{"issue":"4","key":"ysc250005r13","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1097\/j.pain.0000000000002778","article-title":"Microdosing psilocybin for chronic pain: a case series.","volume":"164","author":"Lyes","year":"2023","journal-title":"Pain"},{"issue":"1","key":"ysc250005r14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/jnc.15544","article-title":"Psychedelic-inspired approaches for treating neurodegenerative disorders.","volume":"162","author":"Saeger","year":"2022","journal-title":"J Neurochem"},{"issue":"4","key":"ysc250005r15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin.","volume":"7","author":"Passie","year":"2002","journal-title":"Addict Biol"},{"issue":"12","key":"ysc250005r16","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s40262-017-0540-6","article-title":"Pharmacokinetics of escalating doses of oral psilocybin in healthy adults.","volume":"56","author":"Brown","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"ysc250005r17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/0269881117725915","article-title":"Serotonin and brain function: a tale of two receptors.","volume":"31","author":"Carhart-Harris","year":"2017","journal-title":"J Psychopharmacol"},{"issue":"8023","key":"ysc250005r18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41586-024-07624-5","article-title":"Psilocybin desynchronizes the human brain.","volume":"632","author":"Siegel","year":"2024","journal-title":"Nature"},{"issue":"6","key":"ysc250005r19","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","article-title":"Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.","volume":"47","author":"Holze","year":"2022","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"ysc250005r20","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/pcn.13741","article-title":"Impact of psilocybin on cognitive function: a systematic review.","volume":"78","author":"Meshkat","year":"2024","journal-title":"Psychiatry Clin Neurosci"},{"issue":"4","key":"ysc250005r21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.5960","article-title":"Acute adverse effects of therapeutic doses of psilocybin: a systematic review and meta-analysis.","volume":"7","author":"Yerubandi","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"8","key":"ysc250005r22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ejim.2007.06.033","article-title":"Acute alcohol intoxication.","volume":"19","author":"Vonghia","year":"2008","journal-title":"Eur J Intern Med"},{"issue":"2","key":"ysc250005r23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/phar.1187","article-title":"The pharmacologic and clinical effects of medical cannabis.","volume":"33","author":"Borgelt","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"12","key":"ysc250005r24","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamapsychiatry.2024.2546","article-title":"Adverse events in studies of classic psychedelics: a systematic review and meta-analysis.","volume":"81","author":"Hinkle","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"ysc250005r25","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.675768","article-title":"On perception and consciousness in HPPD: a systematic review.","volume":"15","author":"Vis","year":"2021","journal-title":"Front Neurosci"},{"issue":"4","key":"ysc250005r26","first-page":"296","article-title":"Flashbacks and HPPD: a clinical-oriented concise review.","volume":"51","author":"G Lerner","year":"2014","journal-title":"Isr J Psychiatry Relat Sci"},{"key":"ysc250005r27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/978-3-662-55880-5","article-title":"A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD.","volume":"36","author":"Halpern","year":"2018","journal-title":"Curr Top Behav Neurosci"},{"key":"ysc250005r28","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1199642","article-title":"Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey.","volume":"14","author":"Nayak","year":"2023","journal-title":"Front Psychiatry"},{"issue":"10","key":"ysc250005r29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293349","article-title":"Extended difficulties following the use of psychedelic drugs: a mixed methods study.","volume":"18","author":"Evans","year":"2023","journal-title":"PLoS One"},{"issue":"5","key":"ysc250005r31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1177\/02698811241292956","article-title":"Co-use of psychedelics with other substances: findings from the Global Psychedelic Survey.","volume":"39","author":"Lake","year":"2025","journal-title":"J Psychopharmacol"},{"issue":"12","key":"ysc250005r32","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1177\/0269881118793086","article-title":"Does getting high hurt? characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016.","volume":"32","author":"Leonard","year":"2018","journal-title":"J Psychopharmacol"},{"issue":"4","key":"ysc250005r33","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.3390\/toxins7041018","article-title":"Research on acute toxicity and the behavioral effects of methanolic extract from psilocybin mushrooms and psilocin in mice.","volume":"7","author":"Zhuk","year":"2015","journal-title":"Toxins (Basel)"},{"issue":"1","key":"ysc250005r34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","article-title":"Psychedelic drug legislative reform and legalization in the US.","volume":"80","author":"Siegel","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"ysc250005r35","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.biopsych.2016.01.004","article-title":"Changes in cannabis potency over the last 2 decades (1995\u20132014): analysis of current data in the United States.","volume":"79","author":"ElSohly","year":"2016","journal-title":"Biol Psychiatry"},{"key":"ysc250005r36","doi-asserted-by":"publisher","first-page":"46528","DOI":"10.1038\/srep46528","article-title":"Compromised external validity: federally produced cannabis does not reflect legal markets.","volume":"7","author":"Vergara","year":"2017","journal-title":"Sci Rep"},{"issue":"8","key":"ysc250005r37","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/jamapsychiatry.2020.0927","article-title":"Association of naturalistic administration of cannabis flower and concentrates with intoxication and impairment.","volume":"77","author":"Bidwell","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"ysc250005r38","doi-asserted-by":"publisher","first-page":"21744","DOI":"10.1038\/s41598-021-01128-2","article-title":"Acute objective and subjective intoxication effects of legal-market high potency THC-dominant versus CBD-dominant cannabis concentrates.","volume":"11","author":"Drennan","year":"2021","journal-title":"Sci Rep"},{"issue":"9","key":"ysc250005r39","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1111\/add.16519","article-title":"Changes in self-reported cannabis use in the United States from 1979 to 2022.","volume":"119","author":"Caulkins","year":"2024","journal-title":"Addiction"},{"issue":"22","key":"ysc250005r42","doi-asserted-by":"publisher","first-page":"14068","DOI":"10.3390\/ijms232214068","article-title":"Extensive collection of psychotropic mushrooms with determination of their tryptamine alkaloids.","volume":"23","author":"Gotvaldov\u00e1","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"ysc250005r43","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1177\/0269881115615104","article-title":"The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: a placebo-controlled, double-blind, crossover pilot trial.","volume":"30","author":"Englund","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"8","key":"ysc250005r44","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/cbdv.200790144","article-title":"History of cannabis and its preparations in saga, science, and sobriquet.","volume":"4","author":"Russo","year":"2007","journal-title":"Chem Biodivers"},{"issue":"19","key":"ysc250005r45","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1111\/bph.16466","article-title":"Pharmacological and behavioural effects of tryptamines present in psilocybin-containing mushrooms.","volume":"181","author":"Rakoczy","year":"2024","journal-title":"Br J Pharmacol"},{"issue":"7","key":"ysc250005r46","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1038\/s41380-024-02477-w","article-title":"Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain.","volume":"29","author":"Shahar","year":"2024","journal-title":"Mol Psychiatry"},{"issue":"11","key":"ysc250005r47","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/s41386-023-01607-2","article-title":"Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.","volume":"48","author":"Ley","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"ysc250005r48","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269881118754710","article-title":"Psychedelics and the essential importance of context.","volume":"32","author":"Carhart-Harris","year":"2018","journal-title":"J Psychopharmacol"},{"issue":"2","key":"ysc250005r49","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00213-021-06007-2","article-title":"A naturalistic study of orally administered vs. inhaled legal market cannabis: cannabinoids exposure, intoxication, and impairment.","volume":"239","author":"Bidwell","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"ysc250005r50","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1177\/10600280231205645","article-title":"The tolerability and safety of psilocybin in psychiatric and substance-dependence conditions: a systematic review.","volume":"58","author":"Kaminski","year":"2024","journal-title":"Ann Pharmacother"},{"key":"ysc250005r51","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1134454","article-title":"Therapeutic effect of psilocybin in addiction: a systematic review.","volume":"14","author":"van der Meer","year":"2023","journal-title":"Front Psychiatry"},{"issue":"5","key":"ysc250005r52","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00213-021-05999-1","article-title":"Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey.","volume":"239","author":"Kuc","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"ysc250005r53","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s42238-024-00235-x","article-title":"Simultaneous cannabis and psychedelic use among festival and concert attendees in Colorado: characterizing enhancement and adverse reactions using mixed methods.","volume":"6","author":"Piercey","year":"2024","journal-title":"J Cannabis Res"},{"issue":"6","key":"ysc250005r54","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/nm.4311","article-title":"A chronic low dose of ?9-tetrahydrocannabinol (THC) restores cognitive function in old mice.","volume":"23","author":"Bilkei-Gorzo","year":"2017","journal-title":"Nat Med"},{"issue":"6","key":"ysc250005r55","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.bpsc.2020.07.009","article-title":"Cannabis, cannabinoids, and brain morphology: a review of the evidence.","volume":"6","author":"Chye","year":"2021","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"ysc250005r56","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.724606","article-title":"Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics.","volume":"12","author":"de Vos","year":"2021","journal-title":"Front Psychiatry"},{"key":"ysc250005r57","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108641","article-title":"Psilocybin for dementia prevention? the potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases.","volume":"258","author":"Haniff","year":"2024","journal-title":"Pharmacol Ther"},{"issue":"2","key":"ysc250005r58","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/02791072.1997.10400190","article-title":"Set, setting, and matrix.","volume":"29","author":"Eisner","year":"1997","journal-title":"J Psychoactive Drugs"},{"key":"ysc250005r59","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/978-3-031-12184-5","article-title":"Effects of setting on psychedelic experiences, therapies, and outcomes: a rapid scoping review of the literature.","volume":"56","author":"Golden","year":"2022","journal-title":"Curr Top Behav Neurosci"},{"issue":"12","key":"ysc250005r60","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0269881116677852","article-title":"Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology.","volume":"30","author":"Hartogsohn","year":"2016","journal-title":"J Psychopharmacol"},{"key":"ysc250005r2","doi-asserted-by":"crossref","unstructured":"Patrick? ME, Miech? RA, Johnston? LD, O\u2019Malley? P. Monitoring the Future Panel Study Annual Report: National Data On Substance Use Among Adults Ages 19 to 65, 1976-2023. Institute for Social Research, University of Michigan; 2024. Accessed September 30, 2025. https:\/\/monitoringthefuture.org\/results\/annual-reports\/","DOI":"10.7826\/ISR-UM.06.585140.002.07.0003.2024"},{"key":"ysc250005r30","doi-asserted-by":"crossref","unstructured":"Hooper? J, Williams? S, Mueller? R, Hutchison? K. Age and cannabis co-use moderate experience and perceived benefits of psilocybin.? PsyArXiv. Preprint posted online May 22, 2025. doi:10.31234\/osf.io\/dczw2_v1","DOI":"10.31234\/osf.io\/dczw2_v1"},{"key":"ysc250005r40","unstructured":"Cooke? J. Magic mushrooms 101: everything you need to know before you trip. Accessed September 30, 2025. https:\/\/tripsitter.com\/magic-mushrooms\/"},{"key":"ysc250005r41","unstructured":"Bollinger? I. Preliminary tryptamine potency analysis from dried, homogenized fruit bodies of Psilocybe mushrooms. February 1, 2021. Updated May 23, 2021. Accessed January 25, 2025. https:\/\/www.oaklandhyphae510.com\/post\/preliminary-tryptamine-potency-analysis-from-dried-homogenized-fruit-bodies-of-psilocybe-mushrooms"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2840625\/jamapsychiatry_hutchison_2025_sc_250005_1766508736.94231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:00:24Z","timestamp":1767801624000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2840625"}},"subtitle":["Public Health Challenges of Increasing Publicity, Accessibility, and Use"],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.3038","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}